news

Our latest
Press Releases & Updates

Latest press releases

RetinAI and PulseSight Therapeutics Expand Collaboration to Support Advancement of PST-611 Gene Therapy Program for Geographic Atrophy into Phase 2a

RetinAI and PulseSight Therapeutics expand their collaboration to support PST-611, an investigational gene therapy for geographic atrophy, from AI-based analysis of Phase 1 OCT data through the upcoming Phase 2a trial.

Heidelberg Engineering and RetinAI Expand Ophthalmology Offering with Selected RetinAI Discovery® for Clinics Solutions

RetinAI OCT Atlas® is now CE-marked for Clinical Use: one algorithm for AMD, DR, DME, and Glaucoma

RetinAI OCT Atlas® is now CE-marked under EU MDR 2017/745 for clinical use across AMD, Diabetic Retinopathy, DME, and Glaucoma, validated in the DILL study across 124 patients and three OCT devices.

RetinAI & OptymEdge Collaborate to Accelerate Ophthalmic Drug Development Through AI-Powered Reading Center Solutions

RetinAI on the Top100 Swiss Startups [SEPTEMBER’18]

This year RetinAI has been selected as one of the TOP 100 of Swiss Startups 2018! It’s a great recognition for the team. We are proud of the results we are achieving and we are extremely excited about the future ahead!

Welcome to the new RetinAI [SEPTEMBER'18]

There's nothing permanent except change - Heraclitus. We are incredibly pleased to announce our new logo at RetinAI! This new image reflects our values, strengths and willingness to connect the anatomical and digital worlds to provide a better healthcare for the patient.

Venture Leaders China 2018 [SEPTEMBER'18]

The 10-day business roadshow in China with VentureLab is only a week away! Get to know the Venture Leaders China team member Carlos Ciller, CEO & co-founder of RetinAI before the trip begins! Source: VentureLab.

AGEFI - RetinAI [JULY'18]

RetinAI is honoured to appear in the first page of AGEFI this 5th of July! Another opportunity to highlight how advanced machine learning and artificial intelligence are changing the world of ophthalmic care for the benefit of the patient and healthcare systems worldwide.

‍

Our latest
Press Releases & Updates

Latest press releases

RetinAI and PulseSight Therapeutics Expand Collaboration to Support Advancement of PST-611 Gene Therapy Program for Geographic Atrophy into Phase 2a

Heidelberg Engineering and RetinAI Expand Ophthalmology Offering with Selected RetinAI Discovery® for Clinics Solutions

RetinAI OCT Atlas® is now CE-marked for Clinical Use: one algorithm for AMD, DR, DME, and Glaucoma

RetinAI & OptymEdge Collaborate to Accelerate Ophthalmic Drug Development Through AI-Powered Reading Center Solutions

Latest updates

RetinAI on the Top100 Swiss Startups [SEPTEMBER’18]

Welcome to the new RetinAI [SEPTEMBER'18]

Venture Leaders China 2018 [SEPTEMBER'18]

AGEFI - RetinAI [JULY'18]

Contact us for more informations! We are happy to hear from you!

Sign Up And Receive Our Latest Promotions!

Our latest Press Releases & Updates

Latest press releases

RetinAI and PulseSight Therapeutics Expand Collaboration to Support Advancement of PST-611 Gene Therapy Program for Geographic Atrophy into Phase 2a

Heidelberg Engineering and RetinAI Expand Ophthalmology Offering with Selected RetinAI Discovery® for Clinics Solutions

RetinAI OCT Atlas® is now CE-marked for Clinical Use: one algorithm for AMD, DR, DME, and Glaucoma

RetinAI & OptymEdge Collaborate to Accelerate Ophthalmic Drug Development Through AI-Powered Reading Center Solutions

Latest updates

RetinAI on the Top100 Swiss Startups [SEPTEMBER’18]

Welcome to the new RetinAI [SEPTEMBER'18]

Venture Leaders China 2018 [SEPTEMBER'18]

AGEFI - RetinAI [JULY'18]

Contact us for more informations! We are happy to hear from you!

Our latest
Press Releases & Updates